Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc.

Biotechnology • Healthcare • Burlington, MA, United States • NERV (NCM)

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

617 600 7373 1500 District Avenue, Burlington, MA 01803, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
StocksToTrade • Dec 26
Minerva Neurosciences stock soars after securing $200 million financing - Investing.com
Investing.com • Oct 21
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr - Investing News Network
Investing News Network • Oct 21
Minerva Neurosciences Jumps 339% On $200M Financing Agreement - Nasdaq
Nasdaq • Oct 21
Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative
Quiver Quantitative • Oct 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Minerva Neurosciences, Inc. had layoffs?
No layoff events have been recorded for Minerva Neurosciences, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Minerva Neurosciences, Inc. have?
Minerva Neurosciences, Inc. has approximately 8 employees.
What industry is Minerva Neurosciences, Inc. in?
Minerva Neurosciences, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Minerva Neurosciences, Inc. a publicly traded company?
Yes, Minerva Neurosciences, Inc. is publicly traded under the ticker symbol NERV on the NCM. The company has a market capitalization of approximately $0.18 billion.
Where is Minerva Neurosciences, Inc. headquartered?
Minerva Neurosciences, Inc. is headquartered in Burlington, MA, United States at 1500 District Avenue, Burlington, MA 01803, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.